Overview Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Status: Completed Trial end date: 2009-03-01 Target enrollment: Participant gender: Summary Evaluate the safety and tolerability of escalating oral doses of YM150 in patients undergoing elective primary total knee replacement surgery Phase: Phase 2 Details Lead Sponsor: Astellas Pharma IncTreatments: DarexabanEnoxaparinFactor Xa Inhibitors